Avalon GloboCare extends exclusivity agreement to distribute KetoAir

Avalon GloboCare announces the extension of its exclusive distribution agreement with Qi Diagnostics Limited to distribute the KetoAir, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union. “We are excited to extend our exclusive distribution agreement for KetoAir with Qi Diagnostics,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “KetoAir is the first breathalyzer on the market that uses an AI nutritionist bundled with a nanosensor-based breathalyzer for ketogenic health management. Our primary focus will be on targeting the diabetes reversal and obesity management markets. Given the effectiveness of the ketogenic diet as a treatment option for both diabetes and weight management, we believe there is tremendous potential in addressing these critical health concerns. With the soft launch planned for 2024 and a full-scale launch in 2025, we are excited to bring KetoAir to individuals seeking to enhance their health and wellness journey.”